Cellectis SA - Asset Resilience Ratio
Cellectis SA (CLLS) has an Asset Resilience Ratio of 52.10% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Cellectis SA's Asset Resilience Ratio has changed over time. Check Cellectis SA strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cellectis SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CLLS stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $150.66 Million | 52.1% |
| Total Liquid Assets | $150.66 Million | 52.10% |
Asset Resilience Insights
- Very High Liquidity: Cellectis SA maintains exceptional liquid asset reserves at 52.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cellectis SA Industry Peers by Asset Resilience Ratio
Compare Cellectis SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Cellectis SA (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Cellectis SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.68% | $145.08 Million | $324.72 Million | +14.16pp |
| 2024-12-31 | 30.52% | $117.06 Million | $383.54 Million | +10.44pp |
| 2023-12-31 | 20.08% | $67.11 Million | $334.27 Million | +17.05pp |
| 2022-12-31 | 3.03% | $7.91 Million | $261.22 Million | +2.90pp |
| 2021-12-31 | 0.13% | $499.00K | $382.08 Million | -5.64pp |
| 2020-12-31 | 5.77% | $27.09 Million | $469.47 Million | +1.41pp |
| 2019-12-31 | 4.36% | $20.39 Million | $467.47 Million | +4.28pp |
| 2018-12-31 | 0.08% | $388.00K | $500.84 Million | -12.12pp |
| 2017-12-31 | 12.20% | $40.60 Million | $332.88 Million | +1.16pp |
| 2016-12-31 | 11.04% | $36.51 Million | $330.68 Million | +10.57pp |
| 2014-12-31 | 0.47% | $787.00K | $167.34 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more